The Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA.
J Thromb Haemost. 2010 Jan;8(1):185-93. doi: 10.1111/j.1538-7836.2009.03662.x. Epub 2009 Oct 23.
Endothelial progenitor cells (EPCs) contribute to postnatal neovascularization, thus promoting wide interest in their therapeutic potential in vascular injury and prevention of their dysfunction in cardiovascular diseases. Cleaved high molecular weight kininogen (HKa), an activation product of the plasma kallikrein-kinin system (KKS), inhibits the functions of differentiated endothelial cells including in vitro and in vivo angiogenesis. In this study, our results provided the first evidence that HKa is able to target EPCs and inhibits their tube forming capacity.
We determined the effect of HKa on EPCs using a three-dimensional vasculogenesis assay. Upon stimulation with vascular endothelial growth factor (VEGF) alone, EPCs formed vacuoles and tubes, and differentiated into capillary-like networks. As detected by gelatinolytic activity assay, VEGF stimulated secretion and activation of matrix metallopeptidase 2 (MMP-2), but not MMP-9, in the conditioned medium of 3D culture of EPCs. Specific inhibition or gene ablation of MMP-2, but not MMP-9, blocked the vacuole and tube formation by EPCs. Thus, MMP-2 is selectively required for EPC vasculogenesis. In a concentration-dependent manner, HKa significantly inhibited tube formation by EPCs and the conversion of pro-MMP-2 to MMP-2. Moreover, HKa completely blocked the association between pro-MMP-2 and alphavbeta3 integrin, and its inhibition of MMP-2 activation was dependent on the presence of alphavbeta3 integrin. In a purified system, HKa did not directly inhibit MMP-2 activity.
HKa inhibits tube forming capacity of EPCs by suppression of MMP-2 activation, which may constitute a novel link between activation of the KKS and EPC dysfunction.
内皮祖细胞(EPCs)有助于出生后的血管新生,因此它们在血管损伤中的治疗潜能及其在心血管疾病中功能障碍的预防引起了广泛关注。血浆激肽释放酶-激肽系统(KKS)的激活产物裂解高分子量激肽原(HKa)抑制了包括体外和体内血管生成在内的分化内皮细胞的功能。在这项研究中,我们的结果首次提供了证据,证明 HKa 能够靶向 EPCs 并抑制其管状形成能力。
我们使用三维血管生成测定法来确定 HKa 对 EPCs 的影响。单独用血管内皮生长因子(VEGF)刺激时,EPCs 形成空泡和管腔,并分化为毛细血管样网络。通过明胶酶活性测定法检测到,VEGF 刺激 EPC 三维培养条件培养基中基质金属蛋白酶 2(MMP-2)的分泌和激活,但不激活 MMP-9。特异性抑制或基因敲除 MMP-2,但不抑制 MMP-9,阻断了 EPC 的空泡和管腔形成。因此,MMP-2 是 EPC 血管生成所必需的。HKa 以浓度依赖性方式显著抑制 EPC 的管腔形成和前 MMP-2 向 MMP-2 的转化。此外,HKa 完全阻断了前 MMP-2 与 alphavbeta3 整合素的结合,其对 MMP-2 激活的抑制作用依赖于 alphavbeta3 整合素的存在。在一个纯化的系统中,HKa 不会直接抑制 MMP-2 的活性。
HKa 通过抑制 MMP-2 的激活来抑制 EPC 的管状形成能力,这可能构成 KKS 激活与 EPC 功能障碍之间的新联系。